Hanmi Financial (HAFC) Trades at $30.40 After Triangle; INNOVUS PHARMACEUTICALS (INNV) Shorts Up By 3220%

April 8, 2018 - By Jerrie Dane

INNOVUS PHARMACEUTICALS INC (OTCMKTS:INNV) had an increase of 3220% in short interest. INNV’s SI was 33,200 shares in April as released by FINRA. Its up 3220% from 1,000 shares previously. The SI to INNOVUS PHARMACEUTICALS INC’s float is 0.03%. The stock increased 4.42% or $0.0059 during the last trading session, reaching $0.1395. About 246,139 shares traded. Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) has 0.00% since April 8, 2017 and is . It has underperformed by 11.55% the S&P500.

Hanmi Financial Corporation (HAFC) formed triangle with $31.31 target or 3.00% above today’s $30.40 share price. Hanmi Financial Corporation (HAFC) has $985.92M valuation. The stock decreased 2.88% or $0.9 during the last trading session, reaching $30.4. About 180,017 shares traded. Hanmi Financial Corporation (NASDAQ:HAFC) has risen 2.20% since April 8, 2017 and is uptrending. It has underperformed by 9.35% the S&P500.

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. The company has market cap of $26.86 million. The Company’s products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. It currently has negative earnings. The firm also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence.

Investors sentiment increased to 1.04 in 2017 Q4. Its up 0.16, from 0.88 in 2017Q3. It improved, as 6 investors sold Hanmi Financial Corporation shares while 51 reduced holdings. 17 funds opened positions while 42 raised stakes. 28.39 million shares or 0.61% less from 28.57 million shares in 2017Q3 were reported. First Quadrant Lp Ca invested 0% in Hanmi Financial Corporation (NASDAQ:HAFC). Janney Ltd Liability Corporation reported 0.01% of its portfolio in Hanmi Financial Corporation (NASDAQ:HAFC). Parametric Port Associates Limited Liability invested 0% of its portfolio in Hanmi Financial Corporation (NASDAQ:HAFC). 4,830 were reported by Parallax Volatility Advisers Limited Partnership. Jpmorgan Chase & accumulated 0.01% or 894,955 shares. Guggenheim Cap Limited Liability Corp holds 0% or 47,832 shares in its portfolio. Pnc Grp Inc has invested 0% of its portfolio in Hanmi Financial Corporation (NASDAQ:HAFC). Moreover, Envestnet Asset has 0% invested in Hanmi Financial Corporation (NASDAQ:HAFC). Salzhauer Michael holds 17,914 shares. Rhumbline Advisers holds 0% of its portfolio in Hanmi Financial Corporation (NASDAQ:HAFC) for 78,178 shares. Westwood Hldg Grp Incorporated Inc holds 0.19% or 828,835 shares. 34,200 are owned by New York State Common Retirement Fund. Rothschild Asset Inc reported 136,604 shares. Morgan Stanley owns 0% invested in Hanmi Financial Corporation (NASDAQ:HAFC) for 115,742 shares. Pennsylvania-based Sei has invested 0% in Hanmi Financial Corporation (NASDAQ:HAFC).

Among 7 analysts covering Hanmi Financial (NASDAQ:HAFC), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Hanmi Financial has $39 highest and $26 lowest target. $31.20’s average target is 2.63% above currents $30.4 stock price. Hanmi Financial had 18 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Raymond James given on Tuesday, August 25. The stock has “Market Perform” rating by FIG Partners on Wednesday, October 28. The stock has “Hold” rating by Keefe Bruyette & Woods on Tuesday, August 8. The rating was maintained by Keefe Bruyette & Woods on Friday, October 6 with “Hold”. The firm has “Hold” rating by Keefe Bruyette & Woods given on Monday, June 26. On Wednesday, October 19 the stock rating was downgraded by FIG Partners to “Market Perform”. The firm has “Hold” rating given on Thursday, December 21 by Keefe Bruyette & Woods. FBR Capital maintained it with “Outperform” rating and $39 target in Wednesday, January 25 report. Wood downgraded the shares of HAFC in report on Thursday, June 2 to “Market Perform” rating. The stock of Hanmi Financial Corporation (NASDAQ:HAFC) earned “Neutral” rating by Piper Jaffray on Friday, November 20.

Hanmi Financial Corporation (NASDAQ:HAFC) Institutional Positions Chart